Avadel Pharmaceuticals PLC
AVDL
View Detailed Chart
21.590USD
+0.010+0.05%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
2.10BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.05%
5 Days
+0.56%
1 Month
+0.89%
6 Months
+132.40%
Year to Date
+105.42%
1 Year
+103.49%
View Detailed Chart
TradingKey Stock Score of Avadel Pharmaceuticals PLC
Currency: USD Updated: 2025-12-26Key Insights
Avadel Pharmaceuticals PLC's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 21.06.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avadel Pharmaceuticals PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
10
analysts
Hold
Current Rating
21.056
Target Price
-1.24%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Avadel Pharmaceuticals PLC Highlights
StrengthsRisks
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Undervalued
The company’s latest PE is -12408.05, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 92.83M shares, increasing 3.78% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.86M shares of this stock.
Avadel Pharmaceuticals PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Avadel Pharmaceuticals PLC Info
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Ticker SymbolAVDL
CompanyAvadel Pharmaceuticals PLC
CEODivis (Gregory J)
Websitehttps://www.avadel.com/
FAQs
What is the current price of Avadel Pharmaceuticals PLC (AVDL)?
The current price of Avadel Pharmaceuticals PLC (AVDL) is 21.590.
What is the symbol of Avadel Pharmaceuticals PLC?
The ticker symbol of Avadel Pharmaceuticals PLC is AVDL.
What is the 52-week high of Avadel Pharmaceuticals PLC?
The 52-week high of Avadel Pharmaceuticals PLC is 23.570.
What is the 52-week low of Avadel Pharmaceuticals PLC?
The 52-week low of Avadel Pharmaceuticals PLC is 6.380.
What is the market capitalization of Avadel Pharmaceuticals PLC?
The market capitalization of Avadel Pharmaceuticals PLC is 2.10B.
What is the net income of Avadel Pharmaceuticals PLC?
The net income of Avadel Pharmaceuticals PLC is -48.83M.
Is Avadel Pharmaceuticals PLC (AVDL) currently rated as Buy, Hold, or Sell?
According to analysts, Avadel Pharmaceuticals PLC (AVDL) has an overall rating of Hold, with a price target of 21.056.
What is the Earnings Per Share (EPS TTM) of Avadel Pharmaceuticals PLC (AVDL)?
The Earnings Per Share (EPS TTM) of Avadel Pharmaceuticals PLC (AVDL) is -0.002.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
